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Hepatitis C Methods: A systematic literature search was conducted to identify ran-
domisedcontrolledtrials(RCTs),meta-analyses,andHTAsthatevaluated
initial AVT for CHC. A modified version of the German Hepatitis C Model
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Public Health Research and effectiveness ratio for peginterferon plus ribavirin was € 9,800 per
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(as the next best non-dominated strategy). Sensitivity analyses showed
robust results across a wide range of model parameters.
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Munich, Germany Conclusions:ThisHTAsuggeststhatinitialcombinationtherapyprolongs
life, improves quality of life, and is cost-effective in patients with CHC.
Combination of peginterferon and ribavirin is the most effective and
efficient treatment strategy among the examined options.
Zusammenfassung
Ziel:GegenstanddiesesHealthTechnologyAssessments(HTA),welches
im Auftrag der Deutschen Agentur für HTA (DIMDI/Bundesministerium
für Gesundheit und Soziale Sicherung) durchgeführt wurde, war die
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Research Article OPEN ACCESSsystematische Bewertung der medizinischen Effektivität und der Kos-
teneffektivität antiviraler Therapien bei therapienaiven Patienten mit
chronischerHepatitisCimKontextdesdeutschenGesundheitswesens.
Methoden: Es wurde eine systematische Literaturrecherche zur Identi-
fikation von randomisierten klinischen Studien (RCT), Metaanalysen
und HTAs zur initialen antiviralen Therapie bei chronischer Hepatitis C
durchgeführt. Mit einer modifizierten Version des German Hepatitis C
Model (GEHMO), einem entscheidungsanalytischen Markov-Modell,
wurden Langzeitmorbidität, Lebenserwartung, qualitätskorrigierte Le-
bensjahre (QALY), Lebenszeitkosten und das inkrementelle Kosten-
Nutzwert-Verhältnis(IKNV)fürverschiedeneTherapiestrategienermittelt.
DieModellparameterwurdendeutschenDatenbanken,internationalen
RCTs und einem Cochrane-Review entnommen.
Ergebnisse: Insgesamt erfüllten 9 RCTs, 2 HTA-Berichte, 1 Cochrane
Review und 2 Metaanalysen zur medizinischen Effektivität sowie 7
ökonomische Evaluationen die Einschlusskriterien dieses HTA. Die Su-
stainedVirologicalResponseRaten(SVR)warenamhöchstenfürPegin-
terferon plus Ribavirin mit 54-61%, gefolgt von Interferon plus Ribavirin
mit38-54%undderInterferon-Monotherapiemit11-21%.Ininternatio-
nalenKosten-Effektivitäts-StudienwurdedieKombinationstherapiemit
Interferon und Ribavirin im Vergleich zur Interferon-Monotherapie als
kosteneffektiv eingeschätzt. Publizierte Studien zur Kosteneffektivität
der Kombinationstherapie mit Peginterferon und Ribavirin wurden im
Recherchezeitraum nicht identifiziert. Die Ergebnisse dieses Reviews
wurden in unserer entscheidungsanalytischen Modellierung bestätigt.
Die Kombinationstherapie mit Peginterferon und Ribavirin erzielte im
Vergleich zur Interferon-Monotherapie ein IKNV von 9.800 €/QALY. In
SensitivitätsanalysenzeigtensichrobusteErgebnisseüberweiteBerei-
che der relevanten Modellparameter.
Schlussfolgerung:BasierendaufdenErgebnissendiesesHTAsistdavon
auszugehen,dassantiviraleKombinationstherapienbeitherapienaiven
Patienten die Lebenserwartung erhöhen, die Langzeit-Lebensqualität
verbessern und als kosteneffektiv einzustufen sind. Die Kombinations-
therapiemitPeginterferonundRibavirinbesitztunterdenuntersuchten
Therapien die höchste Effektivität und ist im Vergleich zu anderen im
deutschen Gesundheitswesen akzeptierten medizinischen Verfahren
als kosteneffektiv zu bewerten.
Introduction
Chronic hepatitis C (CHC) is an emerging problem in
publichealth.HepatitisCvirus(HCV)infectsanestimated
170millionpersonsworld-wide,with5millioninWestern
Europe [1]. In Germany, the prevalence of HCV has been
estimated to be 0.5% and the incidence to be 5000 new
infectedpersonsperyear,resultinginmorethan400,000
prevalent cases of chronic hepatitis C [2], [3].
Thevirusimposessignificantpersonalandsocialburdens
on infected individuals, as well as substantial costs to
society. Progression to chronic disease occurs in the
majority of HCV-infected persons [4]. Approximately 20%
ofpatientswithCHCdevelopcompensatedlivercirrhosis
within 20 - 30 years [5], [6], [7], [8], [9], [10], [11], [12],
which is associated with high mortality risk due to liver
failure.
Antiviral combination therapy with interferon alpha and
ribavirin has been considered the standard of care for
treatment-naïvepatientswithchronichepatitisCinfection
and elevated alanine amino transferase (ALT) levels [5],
[13],[14],butrecentmultinationalrandomisedcontrolled
clinical trials [15], [16] showed that combination therapy
with peginterferon alpha and ribavirin yielded higher
sustained virological response rates.
However, antiviral combination therapy is relatively ex-
pensive,raisingthequestionofwhetheritsclinicalbenefit
supports the costs. With rising medical costs and limited
health care budgets, attention is increasingly being fo-
cused not only on the clinical benefits of new drugs but
also on their economic impact. To date no systematic
evaluation of the medical benefits and economic effects
ofantiviraltherapyforpatientswithCHChasbeenunder-
taken in Germany.
Therefore, the German Agency for Health Technology As-
sessment at DIMDI and the German Federal Ministry of
Health and Social Security commissioned this health
technology assessment (HTA). Its objectives were (1) to
systematically review the evidence on effectiveness and
cost-effectivenessofinitialantiviralcombinationtherapy
in patients with CHC, (2) to develop a decision-analytic
Markov model for treatment-naïve patients with CHC for
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analysetheeffectivenessandcost-effectivenessofinitial
antiviral therapy in patients with CHC and elevated ALTs
in Germany.
Research Questions
All research questions of this study were based on a
populationoftreatmentnaïvepatientswithchronichepa-
titis C and elevated ALT levels. The following specific re-
search questions were examined.
1.Howdoestheeffectivenessregardingsustainedvirolo-
gicalresponserate(SVR)comparebetweentheevaluated
antiviral treatment strategies?
2. How does the effectiveness compare between the
evaluated antiviral treatment strategies regarding the
following long-term outcomes?
• Compensated liver cirrhosis
• Decompensated liver cirrhosis
• Hepatocellular carcinoma
• Liver transplantation
• CHC-related mortality
• Total mortality
• Quality-adjusted life expectancy
3. What is the incremental cost-effectiveness of each
antiviraltherapyincomparisontothenextbeststrategy?
4. Which antiviral therapy can be recommended as
standard therapy for the German health care context ac-
cording to effectiveness and cost-effectiveness?
Methods
Systematic Review
Electronic databases, HTA-information networks, and
bibliographic sources were systematically searched to
identifyrandomisedcontrolledtrials(RCT),meta-analyses,
orHTAreportsthatevaluatedinitialantiviralcombination
therapy in patients with CHC (see appendix for search
code in Notes). The time horizon of the literature search
was limited from 1990 to 2002. Study quality and trans-
ferability to the German context were assessed using in-
struments developed by the German Scientific Working
GroupTechnologyAssessmentforHealthCare[17],[18],
[19]. The information was qualitatively summarised in
evidence tables [20]. Results are reported in country-
specific currencies. To facilitate comparison across
countries, all results were additionally converted to US
dollars (US$) of the index year of each study. As currency
conversionmethodsintheindividualstudieswerepoorly
described,weusedexchangeratesexpressedasnational
currency units per US$ instead of applying Purchasing
Power Parities (PPPs) [21].
A meta-analysis of randomised clinical trials on the
medical effectiveness of antiviral combination therapy
with peginterferon plus ribavirin was performed using
random and fixed effects models (REM, FEM). Based on
the standards of the Cochrane Collaboration [22], the
pooled relative risk (RR) for the outcome "No Sustained
Virological Response" with its 95% confidence interval
(CI) was reported. Results were presented as forest plot.
Collaboration and HTA Expert Panel on
Hepatitis C
During this HTA, collaboration was established with the
following institutions:
•CochraneHepato-BiliaryGroup,CopenhagenTrialUnit,
Centre for Clinical Intervention Research, Copenhagen,
Denmark
• Canadian Coordinating Office for Health Technology
Assessment (CCOHTA)
• Robert Koch-Institute, Berlin, Germany
• Federal Institute for Drugs and Medical Devices, Bonn,
Germany
• National Association of Statutory Health Insurance
Physicians, Cologne, Germany
•Hep-Net-GermanNetworkofExcellenceforViralHepa-
titis
Furthermore, the HTA Expert Panel on Hepatitis C was
established for this HTA. This interdisciplinary panel in-
cluded members of the German Hepatitis C Model
(GEHMO) Group and further experts from different areas
whoconsultedinformationconcerningactualunpublished
dataandstudiesandmethodologicalissues.Thelist"HTA
Expert Panel on Hepatitis C" (see Notes at the end of the
article) gives the names, affiliations, and assigned areas
of the expert panel members.
Decision Analysis
A modified version of the German Hepatitis C Model
(GEHMO) was used. This model was designed to include
pooled effectiveness data from meta-analyses, as well
as benefits and costs, for employing different antiviral
treatment strategies for patients with chronic hepatitis
C. Pooled effectiveness data were derived from meta-
analysesperformedbytheHepato-BiliaryCochraneGroup
[23], [24] and additional meta-analyses were performed
by the authors. GEHMO is a decision-analytic Markov
model based on a previously published and validated
Markovmodelforthenaturalhistoryofdisease[25],[26]
and modified for the German health-care system and
German hepatitis C-specific practice patterns.
The model was used to determine long-term morbidity,
life expectancy, quality-adjusted life expectancy, lifetime
costs,anddiscountedincrementalcost-utilityratios(ICUR)
of the following strategies: (1) no antiviral therapy, (2)
interferon monotherapy (3x3 MU/week) for 48 weeks,
(3) combination therapy with interferon (3x3 MU/week)
and ribavirin (1000-1200 mg/day) for 48 weeks, and (4)
combination therapy with peginterferon (180 μg/week
for peginterferon alpha 2a; 1.5 μg/kg for peginterferon
alpha2b)plusribavirin(800-1200mg/day)for48weeks.
According to the European guidelines [5], interferon
monotherapy was stopped after 12 weeks and combina-
tion therapies were stopped after 24 weeks if no virolo-
3/18 German Medical Science 2003, Vol. 1, ISSN 1612-3174
Siebert et al.: Antiviral combination therapy with interferon/ peginterferon ...Table 1: Efficacy data used in the Markov model
gical response was observed at this time. Dosing was
based on European recommendations for patients with
chronichepatitisCandEuropeandrugapprovedlabelling
[5].
Natural history data were estimated from several pub-
lished studies and have been described elsewhere [25],
[26]. Histological classification as mild or moderate
chronic hepatitis or compensated cirrhosis was defined
by the modified histology activity index of Knodell [27],
[28]. For the German context, demographic and clinical
parameters as well as utilities were based on original
datafromaquality-of-lifesurveyinCHCpatients(n=428)
[29], [30]. Utility data included empirically estimated rel-
ativereductionsinshort-termquality-of-lifeduetopositive
HCV status (2%) and adverse events during antiviral
treatment (5% for interferon plus ribavirin and 10% for
peginterferon plus ribavirin).
Our model included pooled short-term outcomes (overall
sustained virological response rates and respective rela-
tive risks) from recently published RCTs and meta-ana-
lyses. Relative virological response rates of interferon
monotherapy and combination therapy with interferon
alpha plus ribavirin were based on a recently published
meta-analysis [23] and a Cochrane Review [24]. We
performed a meta-analysis to derive pooled virological
responseratesofcombinationtherapywithpeginterferon
plus ribavirin published in two randomised clinical multi-
centre trials [15], [16] (see Table 1).
Directannualcostswerecalculatedbasedonfrequencies
of inpatient and outpatient visits, diagnostic and labora-
tory testing, medication, and procedures related to the
specifichealthstates(Table2).Healthresourceutilisation
frequencies were derived from a German expert panel (n
= 10) and an economic survey in chronic hepatitis C pa-
tients (n = 196). Costs were derived from healthcare
databasesandcurrentlyapplicablepharmaceuticalprices
of interferon alpha, peginterferon alpha, and ribavirin in
Germany (Table 3).
A 5% deduction from pharmaceutical prices for the pro-
portionofpersonsinsuredbythesocialhealthinsurance
in Germany was performed. For modelling the costs of
liver transplantation, a study [31] based on German pa-
tient data for the year 1993 was used. All costs were
converted to year 2002 Euros (1 Euro = 1.95583 DM) by
usingthemedicalcarecomponentoftheConsumerPrice
Index for Germany [32]. An annual discount rate of 3%
wasappliedtocostsandeffectivenessbasedoninterna-
tionalrecommendations[33],[34]andvariedinsensitiv-
ity analyses between 0% and 10% regarding German re-
commendations [35].
Model Validation
The decision model was validated on three levels:
•Technicalvalidation:'cleanup'ofthesoftwareprogram
from potential programming bugs
• Internal validation: comparison of model predictions
with epidemiological and clinical data used in the model
• External validation: comparison of model predictions
with published epidemiological data not used in the
model
Thetechnicalvalidationusingdifferentroutinetests(e.g.
setting SVR equal for all strategies, eliminating antiviral
treatment costs, eliminating CHC-related mortality, etc.)
yielded the expected results. In the internal validation,
all data values used were reproduced exactly by the de-
cision model (e.g. SVR rates, progression incidences,
background mortality).
In the external validation, the incidence of developing
compensated liver cirrhosis in patients with mild chronic
hepatitisCwasadjustedforthespontaneousHCV-remis-
sionrateof31%inpatientswithacuteHCV-infection[36].
The model predicted a 20-year incidence of developing
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Table 3: Medication prices for antiviral treatment [60]
compensatedlivercirrhosisof19%inpatientswithinitial
HCV-infection. This result is consistent with published
data from prospective studies [4], [37].
AsthespontaneousHCVremissionrateandtheincidence
of liver cirrhosis have been extracted from different
sources, using different values for spontaneous HCV re-
mission could lead to a proportional deviation from the
cirrhosis incidence used in the validation. However, dif-
ferent rates for spontaneous HCV remission would not
influence results from this model because the target co-
hort of our analysis are patients with chronic hepatitis C.
Sensitivity Analyses
Toassesstherobustnessofbase-caseresults,univariate
sensitivity analyses were performed for all model para-
meters based either on 95% confidence intervals or on
ranges used in the literature. Costs were halved and
doubled to obtain lower and upper limits. In addition to
univariate sensitivity analyses, multivariate sensitivity
analyses were performed on the entire set of disease
progressionrates.Asithasbeenshownthattheprogres-
sion of hepatitis C observed in epidemiologic studies
varies and strongly depends on the study design [8], we
performed conservative sensitivity analyses with ex-
tremelylowprogressionrates.Furthermore,weanalysed
a worst-case scenario using extremely conservative es-
timatesforbenefitsandcostsforthecombinationtherapy
with peginterferon and ribavirin.
Software
Decision analytic calculations were performed with DATA
ProforHealthCare(TreeAgeSoftwareInc.,Williamstown,
MA), SAS 8.1 (SAS Institute Inc., Cary, NC). Systat 10
(SPSS, Inc., Chicago, IL) was used for statistical analyses
of primary data.
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Table 5: Sustained virological response rates (SVR) for peginterferon plus ribavirin versus interferon plus ribavirin.
Results
Systematic Review
Twelve studies regarding the medical efficacy of combin-
ation therapy with interferon plus ribavirin compared to
interferon monotherapy were included; herein 2 HTA re-
ports [38], [39] 1 systematic Cochrane review [24], 2
meta-analyses [23], [40] and 7 controlled randomised
clinical trials [41], [42], [43], [44], [13], [14], [45]. Two
controlled randomised multicentre studies [15], [16] re-
garding medical efficacy of combination therapy with
peginterferon and ribavirin compared to interferon plus
ribavirin were identified and included.
All included studies reported significantly higher SVR for
combination therapy with interferon and ribavirin com-
pared with interferon monotherapy (38-54% vs. 11-21%)
(Table 4). Meta-analyses reported SVRs of 32-41% for
interferon in combination with ribavirin compared to 8-
16% for interferon monotherapy.
For peginterferon combined with ribavirin, multicentre
clinicaltrialsreportedSVRsof54%vs.47%(p-value0.01)
[16] and 56% vs. 44% (p-value < 0.001) [15] compared
to standard combination therapy, respectively (Table 5).
In a subgroup data analysis, one multicentre study [16]
showed that patients treated with a dosage of 10.6 mg
or more ribavirin per kg body weight had higher SVRs.
Sixty-one percent of patients treated with peginterferon
plus ribavirin compared to 48% patients treated with in-
terferon plus ribavirin achieved a sustained virological
response. The pooled relative risk for the outcome 'no
sustained virological response' for the combination ther-
apy with peginterferon plus ribavirin versus interferon
plusribavirinwas0.83(95%CI0.76-0.91forfixedeffects
model and 0.75-0.91 for random effects model). Figure
1 shows the forest plot for the fixed effects model.
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(RR) for no sustained virological response (SVR) for
peginterferon plus ribavirin (PEG-IFN+RBV) versus interferon
plus ribavirin (INF+RBV)
Seven studies including one HTA report [46], [47], [48],
[39], [49], [50], [51] regarding cost-effectiveness of anti-
viral combination therapy with interferon and ribavirin in
patients with chronic hepatitis C were identified in the
search period of this HTA (January 1990 - December
2002), but no publications were found examining cost-
effectivenessofantiviralcombinationtherapywithpegin-
terferon and ribavirin.
Incremental cost-effectiveness ratios varied over a wide
range depending on discount rate, treatment duration,
and population characteristics (Table 6). All studies con-
sidered antiviral therapy with interferon plus ribavirin
seemed to be reasonably cost-effective.
For full evidence tables and results on study quality and
transferability see the online HTA, the full text of which
is available at www.dimdi.de [52].
German Decision Analysis
Based on our decision analysis, initial antiviral therapy
compared to no treatment in patients with chronic hepa-
titis C saved 1.1 life years for interferon monotherapy,
2.9 life years for interferon plus ribavirin, and 4.6 life
years for peginterferon plus ribavirin (Table 7), and re-
duced the 20-year-risk of dying from liver failure by 12%
forinterferonalone,29%forinterferonplusribavirin,and
46% for peginterferon plus ribavirin (Table 8). Compared
tonoantiviraltherapy,interferonmonotherapysaved1.2
quality-adjusted life years (QALY), while combination
therapywithinterferonandribavirinsaved3.0QALYsand
peginterferon plus ribavirin saved 4.8 QALYs.
Afterdiscountingforfuturebenefits,interferonmonother-
apy gained 0.53 QALYs with additional costs of € 2,800
resulting in an ICUR of € 5,300 per QALY compared to no
antiviral therapy (Table 9). Moving from interferon
monotherapy to interferon plus ribavirin was associated
with0.78QALYsgained,additionalcostsof€9,000,and
an ICUR of 11,600 €/QALY. Compared to interferon
monotherapy (as the next best non-dominated strategy),
peginterferon plus ribavirin gained 1.53 QALYs and in-
creased costs by € 14,900 yielding an ICUR of 9,800
€/QALY.Therefore,combinationtherapywithpeginterfer-
onplusribavirinwasthemosteffectivetreatmentstrategy
and was more efficient than interferon plus ribavirin. To
facilitate comparison with ICURs presented in Table 6,
we converted the model-based ICURs for Germany to
2002USdollarsusingthecurrencyexchangerate(US$1
equals €1.07) [21]. When compared to interferon
monotherapy, the ICURs of interferon plus ribavirin and
peginterferon plus ribavirin were 10,800 US$/QALY and
9,200 US$/QALY, respectively.
In sensitivity analyses, results were robust when varying
most relevant model parameters. Even when reducing
SVRto50%,combinationtherapywithpeginterfe-ronplus
ribavirin was still the most effective strategy. Peginterfer-
on plus ribavirin remained the most effective and cost-
effectivestrategywhenvaryingtheproportionofpatients
with compensated cirrhosis from 0% to 52%, the propor-
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combination therapy with interferon plus ribavirin (24 or 48 weeks) vs. interferon monotherapy (48 weeks) in treatment-naїve
patients with chronic hepatitis C
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Table 6: Discounted incremental cost-effectiveness-ratios (ICER) and discounted incremental cost-utility-ratios (ICUR) for
combination therapy with interferon plus ribavirin (24 or 48 weeks) vs. interferon monotherapy (48 weeks) in treatment-naїve
patients with chronic hepatitis C
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Table 8: Twenty-year-risk for clinical events, life expectancy, and quality-adjusted life expectancy (undiscounted).*
tion of male CHC-patients from 20% to 100%, or when
body weight was increased by 20%.
Several sensitivity analyses were performed on progres-
sion rates. In a conservative scenario, the 20-year inci-
dence of compensated cirrhosis was set to 7% as repor-
ted in a meta-analysis of results from community-based
studies [8]. This scenario is conservative, because the
study population of community-based studies included
38% of patients with normal ALT levels which is associ-
ated with a reduced risk of developing liver cirrhosis
compared to our target population of CHC-patients with
elevated ALT levels [53]. Figure 2 demonstrates the im-
pact of progression on the ICUR of antiviral combination
therapy.Evenwitha20-year-incidenceofcirrhosisofonly
7%, as reported in community studies [8], peginterferon
plus ribavirin was the most effective therapy and, with
an ICUR of 21,100 €/QALY, was still reasonably cost-ef-
fective. When we further removed the 2% quality-of-life
reduction due to HCV-infection in viral-positive CHC pa-
tients in this conservative scenario, the ICUR increased
to 26,200 €/QALY.
Intheworst-casescenario,whichwasperformedtoobtain
extremely conservative estimates for benefits (e.g., SVR)
andcostsforthecombinationtherapywithpeginterferon
and ribavirin, peginterferon plus ribavirin was the most
effective treatment strategy and resulted in an ICUR of
27,300€/QALYcomparedtothenextbestnon-dominated
strategy (i.e., interferon monotherapy).
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Figure 2: Influence of disease progression rate on the incremental cost-utility-ratio of antiviral combination therapy. Disease
progression is described as 20-year incidence of compensated liver cirrhosis in initial HVC-infected patients (including acute
hepatitis C).
Discussion
Inthishealthtechnologyassessment,asystematicevalu-
ation of the medical efficacy and cost-effectiveness of
antiviral combination therapy as an initial treatment for
patients with chronic hepatitis C was performed. In addi-
tion, a modified version of the German Hepatitis C Model
(GEHMO)wasappliedtopredictthe20-yearrisksofCHC-
related liver diseases, life expectancy, quality-adjusted
lifeexpectancy,lifetimecosts,andincrementalcost-utility
ratio for different antiviral treatment strategies and for
the German health care context.
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[45]andmeta-analyses[23],[24],[40]reportedcombin-
ation therapy with interferon plus ribavirin to be more
efficient than interferon monotherapy (SVR: 32-54% vs.
8-21%). Two randomised multicentre studies [15], [16]
reported a higher SVR for peginterferon plus ribavirin
compared to combination therapy with interferon plus
ribavirin (54-56% vs. 44-47%).
In terms of life expectancy and quality-adjusted life ex-
pectancycombinationtherapywithinterferonplusribavi-
rinwasmoreeffectiveandalsoreasonablycost-effective
when compared to interferon monotherapy, based on
international cost-effectiveness studies [46], [47], [48],
[39], [49], [50], [51].
In our decision analysis for the context of the German
healthcaresystem,initialantiviraltherapywithinterferon
and ribavirin compared to interferon monotherapy had a
discounted ICUR of 11,600 €/QALY. Compared to inter-
feron monotherapy, peginterferon plus ribavirin cost €
14,900 and gained 1.53 QALYs, resulting in an ICUR of
9,800 €/QALY. Therefore, combination therapy with pe-
ginterferonplusribavirinwasthemosteffectiveandcost-
effective treatment strategy.
Compared to other well-accepted medical interventions,
e.g., hemodialysis [54] or coronary artery bypass grafts
[55] with ICURs of 50,000 to 60,000 €/QALY, combina-
tion therapy with peginterferon and ribavirin can be con-
sidered as cost-effective.
As is the case with all model-based cost-effectiveness
analyses, ours has several limitations due to the availab-
ility of data on the natural history of chronic hepatitis C.
Theriskofprogressiontocirrhosisisespeciallycontrover-
sially. In a recently published review of 57 studies on the
natural history of hepatitis C [8], the authors classified
theidentifiedstudiesintofourcategoriesofstudydesign
andusedregressionanalysistoderivepooledprogression
estimates for each category. The estimated 20-year risk
of cirrhosis was 24% for post-transfusion cohorts, 22%
for liver clinic series, 7% for community-based cohorts,
and 4% for blood donors. Adjusting for demographic and
clinical characteristics explained only a small part of the
heterogeneity. It has been argued that biases such as
referral bias and selection bias may explain the high cir-
rhosis risks in liver series and post-transfusion cohorts
as well as the low estimates in blood donors [7]. The
fraction of patients with elevated ALT levels varied
between these different settings and was as low as 62%
in the community-based studies [8].
The target population of our study was a patient cohort
withelevatedALTvaluesandamixofdifferenthistological
stages as observed in clinical trials and routine clinical
practice in the absence of systematic screening. Post-
transfusion studies were the only category that required
thepresenceofclinicalorbiochemicalhepatitis,andthus
may be the category that best represents the advanced
disease stage of the population we studied. However,
transfusion may be associated with underlying chronic
disease, which itself may influence the progression of
hepatitis [7]. In community-based studies, most patients
had normal ALT values, and some studies included pa-
tients with acute hepatitis C. Thus, these studies do not
reflect the decision context and the population we stud-
ied. However, even after reducing the progression rates
of our model to the extent that 20-year cirrhosis risk was
only 7% (i.e., reflecting the community-based estimate),
theICURforcombinationtherapywithpeginterferonplus
ribavirin remained below 22,000 €/QALY. This indicated
the robustness regarding the optimal choice among the
evaluated strategies even under very conservative as-
sumptions.
However, the results may be different for patients with
normalALTlevels,withacutehepatitisC,orinpopulations
in which a systematic screening for HCV was performed
and, therefore, most cases were detected in a very early
stage of the disease. For an evaluation in these popula-
tions, the decision model and its data must be adapted
tothespecificcontext.Inparticular,thismeansthateven
if future studies yield good SVRs in screened patients or
patients with normal ALT values, long-term effectiveness
or cost-effectiveness cannot be automatically inferred
from these results without additional decision analyses.
Forpeginterferonplusribavirin,theestimationofmedical
efficacy was based on only 2 studies [15], [16], the only
publishedrandomisedclinicalmulticentretrials.However,
the results of these two trials were similar, and our de-
cision analysis results remained robust when varying the
SVR in sensitivity analyses. More evidence should be re-
trievedfromadditionalrandomisedclinicaltrialscompar-
ing combination therapy with peginterferon plus ribavirin
to standard combination therapy.
Severe adverse events may occur more frequently in pa-
tients treated with peginterferon plus ribavirin than in
patients treated with interferon plus ribavirin [15], [16].
As the absolute number of adverse events was small,
andnoutilitydatawereavailableforeachtypeofadverse
event,wewereunabletodevelopamicromodelforsevere
adverse events. Instead, we empirically estimated the
overall relative reduction in quality of life due to different
antiviral treatment regimens from the German CHC
quality-of-life survey.
Our economic analysis likely underestimates disease-re-
lated costs for several reasons, and therefore likely un-
derestimatestreatment-relatedsavingsduetoprevented
future complications. First, we used variable costs and
did not consider fixed costs nor costs due to productivity
loss. Second, our model does not include the cost of fu-
tureliverbiopsiesandfurthertherapyfornon-responders.
Third, we did not consider histology normalisation in re-
sponders, nor reduced incidence of hepatocellular car-
cinoma in non-responders.
This analysis applied average age, gender distribution,
genotype distribution, and histology to avoid potential
biases related to patient-level variation in the different
treatment groups of the trials and applied a consistent
resourceutilisationstructureinthemodelandinstitution-
al assignment (where different institutions across Ger-
manymayvaryintheireconomicefficienciesandaccount-
ing practices).
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Country to country differences in sociodemographic
structure,distributionofpatient'sclinicalcharacteristics,
utility profiles, resource utilisation, and prices make it
difficult, if not impossible, to transfer the results of our
qualitativereviewofeconomicevaluationstootherhealth-
care systems and countries [56], [57], [58], [19], [59].
However, the cost-effectiveness patterns for interferon
andribavirininotherindustrialisedcountriesweresimilar
to the results derived from the German decision model.
As none of the included economic evaluations examined
the cost-utility ratio of peginterferon plus ribavirin, the
German model results are currently the only data for this
new treatment.
Futurestudiesshouldexaminetheefficacyandtheneed
for antiviral therapy in patients with normal ALT levels,
with histological mild hepatitis C, and with certain risk
and comorbidity profiles (e.g., HIV infection, intravenous
drug users, haemophilia, etc.). All clinical trials used the
sustainedvirologicalresponserateasasurrogatemarker
for the clinical efficacy. Further epidemiological studies
evaluatinglong-termclinicaloutcomes(e.g.,incidenceof
cirrhosis,mortality)shouldbeperformedtoprovidemore
evidence on the long-term benefit of antiviral therapy.
Furthermore, further research is needed regarding the
natural progression of the disease considering different
prognosticfactors.Moreobservationallong-termstudies
on the natural history of hepatitis C and the medical ef-
fectiveness of different therapeutic strategies should be
performed, as well as prospective studies assessing ac-
tual cost for treatment and side effects in the routine
health care setting.
Conclusions
This HTA suggests that initial combination therapy for
chronic hepatitis C should prolong life, improve quality-
adjusted life expectancy, and be cost-effective. The
combination of pegylated interferon and ribavirin is cur-
rently the most effective and efficient antiviral treatment
for CHC.
However, because not all chronic hepatitis C patients will
developprogressiveliverdisease,athoroughassessment
of the eligibility and appropriateness of treatment with
combination therapy requires a careful discussion
between patients and physicians. This discussion must
consider the demographic and clinical characteristics of
the patient and the trade-offs between the expected
prognosis, side effects, and the willingness to consider
antiviral treatment to prevent potential future liver com-
plications.
Notes
Appendix: Literature Search Strategy
ThecodeinTable10representstheOVIDsearchstrategy
used for identifying clinical and economic studies on an-
tiviral combination therapy for chronic hepatitis C in
MEDLINE and PreMEDLINE. Similar searches were per-
formedinEMBASE,CochraneLibrary,BestEvidence,NHS
HTA databases (DARE, NHS EED, HTA), EconLit, Health
ServicesResearchProjectsinProgress(HSRPROJ),Health
Services/Technology Assessment (HSTAT), International
Health Technology Assessment (IHTA), Catalog Online
(CATLINE), and Science Citation Index (Science Citation
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Index Expanded, Social Science Citation Index and Arts
&HumanitiesCitationIndex).TheHTAcovereddocuments
publishedbetween1990andDecember2002.Line#15
and line #20 represent the final codes for studies on
clinicaleffectivenessandeconomicstudies,respectively.
HTA Expert Panel on Hepatitis C
See Table 11.
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